title: Treatment and cost implications of pertuzumab.
authors.forename: Michael E
authors.initials: ME
authors.lastname: Chernew
authors.forename: Lee N
authors.initials: LN
authors.lastname: Newcomer
authors.forename: Sandra M
authors.initials: SM
authors.lastname: Swain
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000191:economics* / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy; D017326:Clinical Trials, Phase III as Topic; D016527:Drug Costs; D005260:Female; D017048:Health Care Costs; D006801:Humans; D016032:Randomized Controlled Trials as Topic; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000037:antagonists & inhibitors; D014481:United States
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D018719:Erb-b2 Receptor Tyrosine Kinases; C485206:pertuzumab